Drug Guidance

Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

-

Drug guidance

Onasemnogene abeparvovec for treating spinal muscular atrophy

-

Drug guidance

Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer

-

Drug guidance

Selexipag for treating pulmonary arterial hypertension

Drug guidance

Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer

-

Drug guidance

Alectinib for adjuvant treatment of resectable, ALK mutation-positive non-small-cell lung cancer

-

Drug guidance

Dostarlimab for treating primary advanced or recurrent endometrial cancer

Drug guidance

Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes

-

Drug guidance

Aflibercept and faricimab for treating macular oedema secondary to retinal vein occlusion

-

Drug guidance

Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis

-

Drug guidance